ATNM - Actinium Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Actinium Pharmaceuticals, Inc.

275 Madison Avenue
7th Floor
New York, NY 10016
United States
646-767-3870
http://www.actiniumpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. Sandesh C. SethChairman & CEO825kN/A1964
Mr. Steven O'Loughlin BSPrincipal Financial & Accounting Officer360kN/A1986
Dr. Dale L. Ludwig Ph.D.Chief Scientific Officer323.77kN/A1962
Dr. Mark S. BergerChief Medical Officer475kN/A1955
Mr. Anil KapurChief Commercial Officer294.4kN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Corporate Governance

Actinium Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.